Researchers investigated the use of statins to decrease 28-day mortality among VAP patients. The therapy had initially shown promising results in other studies.
After measuring 28-day, 14-day, intensive care unit and hospital mortality rates between a VAP group receiving statins and a VAP group receiving a placebo, researchers concluded there were no statistically significant differences in survival, and statins were no more effective than a placebo in improving any of the measured mortality rates.
More Articles on Quality:
Blame Game Keeps Healthcare Workers Stuck in Hand Hygiene Compliance Slump
Preventing Needless Hospital Deaths: Q&A With Dr. Ira Williams, Author of “Find the Black Box”
Compounding Pharmacy Meningitis Outbreak Caused 61 Deaths, 749 Infections, Study Says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
